Big Pharma deal in Shanghai, page-2

Good work.

@Hoyland .....
"Benitec also uses gene therapy vectors to deliver the DNA, West said, pointing to BB-201 in wet age-related macular degeneration (AMD). In nonhuman primates, gene therapy viral vectors successfully delivered the ddRNAi technology to the back of the eye via intravitreal injection."

My understanding is that the vector has been delivered to NHPs, not the construct. I could easily be missing something here. Efficacy testing, on rodents and NHPs is upcoming.

R&D cheque could anytime in the next couple of months, another $3m me thinks.

Also, don't forget, half yearly report is due very soon. Won't have much new news, but should provide some positive insight.